Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies

Nicolas Batty, Joseph Shatzel, Samuel Wiles, Mathew Kabalan, Rohit Sharma, Jonathan Pang, David Yi, Iris Alatovic, Sana Saif, Deepika Narasimha, Joseph LaPenna, Anthony Troitino, Kristopher Attwood, Michael Weinstein, Eric Murawski, Mathew Valerio, Yong Yin, Meir Wetzler

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Background: As novel therapies in oncology and in particular hematological malignancies impose a high financial burden with a limited increase in life expectancy. Therefore, CEA is important to evaluate the value of new therapies. However, there is a dire need to critically evaluate how valid are such studies. Aims: To review and critically analyze the methodology used to conduct CEAs within the hematologic malignancies disease. Methods: We conducted a PubMed search using the following keywords and combined searches: CEAs, hematological malignancies leukemia, lymphoma and myeloma. Results: Available data showed that systemic reviews of CEA of hematological malignancies to assess whether reviewers have not sufficiently cited deficiencies in their methodologies, or stated clearly the impact of sponsorship and publication biases. Conclusion: Despite the paucity of the literature, sponsorship bias was found to be a major concern in the validity of these analyses.

Original languageEnglish
Pages (from-to)40-44
Number of pages5
JournalJournal of Cancer Policy
Issue number2
StatePublished - Jun 2014


  • Cost effectiveness analysis
  • Deficiencies
  • Hematological malignancies
  • Methodologies
  • Oncology


Dive into the research topics of 'Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies'. Together they form a unique fingerprint.

Cite this